Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Elyse A. Olesinski"'
Autor:
Sarah E. Valentine, Cara Fuchs, Elyse A. Olesinski, Natalya Sarkisova, Laura B. Godfrey, A. Rani Elwy
Publikováno v:
Implementation Science Communications, Vol 4, Iss 1, Pp 1-15 (2023)
Abstract Background Successful implementation of evidence-based treatments (EBT) for posttraumatic stress disorder (PTSD) in primary care may address treatment access and quality gaps by providing care in novel and less stigmatized settings. Yet, PTS
Externí odkaz:
https://doaj.org/article/126db84840884f24885877d2ed6234fd
Autor:
Elyse A. Olesinski, Shruti Bhatt
Publikováno v:
STAR Protocols, Vol 2, Iss 2, Pp 100461- (2021)
Summary: The clinical effectiveness of BH3 mimetics therapy is limited by the inevitable emergence of acquired resistance. We present a protocol to model in vivo acquired resistance to BH3 mimetics in patient-derived xenograft (PDX) mouse models of a
Externí odkaz:
https://doaj.org/article/8dd8e21e8b9e414aa297f912c8203ae4
Autor:
Elyse A Olesinski, Karanpreet S Bhatia, Aarthi Nivasini Mahesh, Shazwina Rosli, Jameelah S Mohamed, Wei Ying Jen, Nitin Jain, Jacqueline S. Garcia, Gee Chuan Wong, Melissa G Ooi, Anthony Letai, Marina Y. Konopleva, Shruti Bhatt
Publikováno v:
Blood Advances.
Background Successful implementation of evidence-based treatments (EBT) for posttraumatic stress disorder (PTSD) in primary care may address treatment access and quality gaps by providing care in novel and less stigmatized settings. Yet, PTSD treatme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::233a59b07c4f4e113369724acfc7a621
https://doi.org/10.21203/rs.3.rs-895692/v1
https://doi.org/10.21203/rs.3.rs-895692/v1
Autor:
Elyse Ann Olesinski, Marina Konopleva, Nitin Jain, Anthony Letai, Shruti Bhatt, Karanpreet Singh Bhatia, Jacquelin S Garica
Early T-cell precursor (ETP) acute lymphoblastic leukemia (T-ALL) is a high-risk subtype of T-ALL and is associated with poor survival outcomes with chemotherapy. We previously showed that maturation stage of thymocytes distinguishes pro-survival dep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98476732345de2b29233f432ae0a5c96
https://doi.org/10.1101/2021.08.19.456932
https://doi.org/10.1101/2021.08.19.456932
Autor:
Sophia Adamia, Shruti Bhatt, Marissa S. Piosos, Thelma Mashaka, Elyse A. Olesinski, Jeremy Ryan, Jacqueline S. Garcia, Buon Leutz, Anthony Letai, Binyam Yilma, David M. Weinstock
Publikováno v:
Cancer Research. 81:NG14-NG14
Relapse is the leading cause of treatment failure in acute myeloid leukemia (AML) patients. FDA approval of 8 targeted therapies in the past two years has drastically altered the landscape of AML treatment. Despite this success, the duration of clini
Autor:
Mikolaj Slabicki, Eric Kuhn, Quinlan L. Sievers, Namrata D. Udeshi, Jessica A. Gasser, Adam S. Sperling, Rob S. Sellar, Hasmik Keshishian, Michael Burgess, Elyse A. Olesinski, Benjamin L. Ebert, Steven A. Carr, Rohan Sharma, Anthony Letai, Peter Miller, Shruti Bhatt, Max Jan, Brian J. Liddicoat, Mariateresa Fulciniti, Emma C. Fink, Dylan N. Adams, Nikhil C. Munshi
Publikováno v:
Blood. 134(2)
Pharmacologic agents that modulate ubiquitin ligase activity to induce protein degradation are a major new class of therapeutic agents, active in a number of hematologic malignancies. However, we currently have a limited understanding of the determin
Autor:
Ensar Halilovic, Elyse A. Olesinski, David M. Weinstock, Holly Zhu, Sophia Adamia, Leutz Buon, Jeremy Ryan, Shruti Bhatt, Morris Erick, Marissa S. Pioso, Binyam Yilma, Anthony Letai, Youzhen Wang, Jacqueline S. Garcia
Publikováno v:
Blood. 134:2551-2551
BCL-2 antagonist venetoclax combined with hypomethylating agents or low-dose cytarabine is a new standard of care for treatment-naive elderly or unfit AML patients. Despite the striking overall response of 70%, only 30% achieved MRD negative status w